FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121853412> ?p ?o ?g. }

• W2121853412 endingPage "e006645" @default.
• W2121853412 startingPage "e006645" @default.
• W2121853412 abstract "<h3>Background</h3> Adalimumab and ustekinumab have demonstrated high effectiveness in the treatment of moderate-severe psoriasis in randomised controlled trials. There is, however, limited data available on the comparative effectiveness of ustekinumab and adalimumab in psoriasis patients unsuccessfully treated with a first biologic line with etanercept. <h3>Purpose</h3> To evaluate the comparative effectiveness of adalimumab and ustekinumab in patients previously treated with etanercept using PASI 90 score. <h3>Material and methods</h3> A single-centre, retrospective, observational, comparative study was carried out from 1 November 2011 to 31 November 2015. Participants were patients with moderate-severe psoriasis that, after unsuccessful etanercept therapy, were treated with adalimumab or ustekinumab. An unblinded revision of each patient’s clinical history was carried out to assess clinical data. The primary analysis compared the percentages of patients in each treatment group who achieved ≥90% improvement from baseline PASI score (PASI 90) at week 12. Secondary endpoints included percentages of patients with PASI 90 at week 96. Statistical analysis was performed with the SPSS 22.0 software. <h3>Results</h3> Thirty-four psoriasis patients were included in the study: 15 (44.1%) patients received adalimumab and 19 (55.9%) received ustekinumab as a second-line therapy. The median age in adalimumab and ustekinumab group were 58 (SD 6.7) and 50 years (SD 17.3) (p=0.08). After 12 weeks of study treatment, 68.4% of ustekinumab-treated patients (13/19) achieved a PASI 90 response against 46.6% (7/15) in the adalimumab group (p=0.2). At week 96, more patients had a PASI 90 in the ustekinumab group compared with the adalimumab group, but the difference was not statistically significant (68.4% versus 46.6%; p=0,2). <h3>Conclusion</h3> Previously studies have shown that adalimumab and ustekinumab are effective after anti-TNF inhibitors’ therapy. However, to our knowledge, the present study is the first to evaluate the comparative effectiveness measured as PASI 90 of ustekinumab and adalimumab in psoriasis patients that failed with etanercetp. Our results suggests that there is no significant difference in the efficacy of ustekinumab between ustekinumab and adalidumab in the percentage of patients achieving PASI90. Of course, these results need to be evaluated with randomised and prospective clinical trials. <h3>References and/or Acknowledgements</h3> 1. J Dermatolog Treat2015;26(3):217–22. 2. J Eur Acad Dermatol Venereol2011;25(9):1037–40. No conflict of interest" @default.
• W2121853412 created "2016-06-24" @default.
• W2121853412 creator A5037807756 @default.
• W2121853412 creator A5085315182 @default.
• W2121853412 date "2014-12-01" @default.
• W2121853412 modified "2023-10-15" @default.
• W2121853412 title "A Frailty Instrument for primary care for those aged 75 years or more: findings from the Survey of Health, Ageing and Retirement in Europe, a longitudinal population-based cohort study (SHARE-FI75+)" @default.
• W2121853412 cites W1524996874 @default.
• W2121853412 cites W1908294898 @default.
• W2121853412 cites W1918525990 @default.
• W2121853412 cites W1963685752 @default.
• W2121853412 cites W1966728931 @default.
• W2121853412 cites W1967974729 @default.
• W2121853412 cites W1975412844 @default.
• W2121853412 cites W1984052936 @default.
• W2121853412 cites W1988183420 @default.
• W2121853412 cites W1988599136 @default.
• W2121853412 cites W1989930174 @default.
• W2121853412 cites W1990844145 @default.
• W2121853412 cites W1994646016 @default.
• W2121853412 cites W1995916672 @default.
• W2121853412 cites W1998940826 @default.
• W2121853412 cites W1999215283 @default.
• W2121853412 cites W2018946485 @default.
• W2121853412 cites W2024684446 @default.
• W2121853412 cites W2026733709 @default.
• W2121853412 cites W2026863320 @default.
• W2121853412 cites W2030061020 @default.
• W2121853412 cites W2032348172 @default.
• W2121853412 cites W2037844081 @default.
• W2121853412 cites W2040106350 @default.
• W2121853412 cites W2047385816 @default.
• W2121853412 cites W2048256797 @default.
• W2121853412 cites W2057003716 @default.
• W2121853412 cites W2065401173 @default.
• W2121853412 cites W2069096555 @default.
• W2121853412 cites W2071268663 @default.
• W2121853412 cites W2083113766 @default.
• W2121853412 cites W2091955463 @default.
• W2121853412 cites W2092170177 @default.
• W2121853412 cites W2092705208 @default.
• W2121853412 cites W2095649880 @default.
• W2121853412 cites W2100248381 @default.
• W2121853412 cites W2102058743 @default.
• W2121853412 cites W2103162037 @default.
• W2121853412 cites W2104750100 @default.
• W2121853412 cites W2114656311 @default.
• W2121853412 cites W2116041825 @default.
• W2121853412 cites W2122006069 @default.
• W2121853412 cites W2123464099 @default.
• W2121853412 cites W2125050797 @default.
• W2121853412 cites W2127128397 @default.
• W2121853412 cites W2128529067 @default.
• W2121853412 cites W2132582362 @default.
• W2121853412 cites W2132994394 @default.
• W2121853412 cites W2135206083 @default.
• W2121853412 cites W2136239977 @default.
• W2121853412 cites W2142514031 @default.
• W2121853412 cites W2143261494 @default.
• W2121853412 cites W2152456824 @default.
• W2121853412 cites W2155858865 @default.
• W2121853412 cites W2158639922 @default.
• W2121853412 cites W2159294672 @default.
• W2121853412 cites W2160611838 @default.
• W2121853412 cites W2160668773 @default.
• W2121853412 cites W2163381389 @default.
• W2121853412 cites W2164059021 @default.
• W2121853412 cites W2166349035 @default.
• W2121853412 cites W2167607311 @default.
• W2121853412 cites W2177168494 @default.
• W2121853412 cites W2313038141 @default.
• W2121853412 cites W2408922987 @default.
• W2121853412 cites W2472887549 @default.
• W2121853412 cites W2477241100 @default.
• W2121853412 cites W336034 @default.
• W2121853412 doi "https://doi.org/10.1136/bmjopen-2014-006645" @default.
• W2121853412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4275665" @default.
• W2121853412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25537787" @default.
• W2121853412 hasPublicationYear "2014" @default.
• W2121853412 type Work @default.
• W2121853412 sameAs 2121853412 @default.
• W2121853412 citedByCount "55" @default.
• W2121853412 countsByYear W21218534122013 @default.
• W2121853412 countsByYear W21218534122015 @default.
• W2121853412 countsByYear W21218534122016 @default.
• W2121853412 countsByYear W21218534122017 @default.
• W2121853412 countsByYear W21218534122018 @default.
• W2121853412 countsByYear W21218534122019 @default.
• W2121853412 countsByYear W21218534122020 @default.
• W2121853412 countsByYear W21218534122021 @default.
• W2121853412 countsByYear W21218534122022 @default.
• W2121853412 countsByYear W21218534122023 @default.
• W2121853412 crossrefType "journal-article" @default.
• W2121853412 hasAuthorship W2121853412A5037807756 @default.
• W2121853412 hasAuthorship W2121853412A5085315182 @default.
• W2121853412 hasBestOaLocation W21218534121 @default.
• W2121853412 hasConcept C126322002 @default.
• W2121853412 hasConcept C16005928 @default.

• next